Opinion

Video

First-Line Treatment Options in HR+/HER2- and Challenges with Treatment Resistance

Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, delve into the most clinically significant genomic tests and biomarker assays employed in HR+/HER2- breast cancer, focusing on BRCA mutations, PI3 alterations, AKT alterations, and PTEN alterations, which play crucial roles in determining prognosis and guiding treatment decisions.

  1. What is your approach to selecting a first-line treatment options for HR+/HER2- breast cancer? Please provide a high-level overview of SOC treatment options in the first-line?
    1. What are primary considerations in selecting a first-line treatment?
  2. What proportion of patients with HR+/HER2- breast cancer experience resistance to first-line endocrine therapy (ET) + CDK4/6 inhibitor?
    1. What does disease progression after first-line treatment look like?
    2. What is the typical timing of disease progression after first-line treatment?
Related Videos
5 KOLs are featured in this panel.
5 KOLs are featured in this panel.
Andrew Davis, MD
2 KOLs are featured in this panel.
2 KOLs are featured in this panel.
Video 6 - 2 KOLs are featured in, "Other trials of note investigating targeted therapies in later line HR+/HER2- mBC"
Video 5 - 2 KOLs are featured in, "Targeted Therapies in HR+/HER2- mBC: CAPItello-291"
A panel of 3 experts on CLL
A panel of 3 experts on CLL
4 KOLs are featured in this series